ICON stock has given investors a difficult backdrop over the past three years, with the share price declining 36.3%, yet current checks suggest the market price may now sit below most estimates of intrinsic value. With both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples pointing to undervaluation, the focus turns to whether that gap is justified by the company’s risk and return profile.

• ICON shares are down 36.3% over the past three years. This leaves recent holders under pressure and puts more attention on whether the current price already reflects key risks.
• The new multi year collaboration with Anthropic to apply AI across the clinical trial lifecycle can support expectations for future cash flows, while the recent US$2.15b senior notes offering highlights refinancing and balance sheet risks that investors still need to factor in.
• ICON screens as undervalued on 5 of 6 checks, so the broader valuation work leans cheap rather than expensive, as reflected in its 5 out of 6 value score.

The issue now is whether ICON’s current discount to intrinsic value offers enough compensation for the execution and financing risks that come with its AI push and debt structure.

Is ICON Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model looks at the cash ICON can generate for shareholders and works back to an implied value today. ICON’s latest twelve month free cash flow is about $1.02b, and the model assumes this cash generation continues to grow rather than shrink over time. On that basis, the 2 Stage Free Cash Flow to Equity framework points to an estimated intrinsic value of about $234 per share.

Compared with the current share price, this suggests ICON trades at roughly a 29.6% discount and therefore appears undervalued on cash flow grounds. The multi year collaboration with Anthropic on AI for clinical trials helps explain why the DCF still supports a higher value, because it ties future cash flows to a concrete execution plan rather than a vague story.

Overall, the cash flow work indicates ICON stock currently appears undervalued relative to what its projected free cash flows support.

Our Discounted Cash Flow (DCF) analysis suggests ICON is undervalued by 29.6%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.

Does ICON Look Undervalued on Sales?

P/S is often a useful cross-check for a company like ICON, where revenue is a key driver for long-term cash generation.

ICON currently trades on a P/S of about 1.5x. This sits well below both the Life Sciences industry average P/S of about 4.1x and the peer average of about 5.1x. The fair P/S ratio for ICON, which adjusts for its size, margin profile and risk, is estimated at about 3.2x. That is a clear gap to where the stock trades today on sales.

On this framework, ICON screens as undervalued on revenue. The P/S suggests the market is applying a wide discount to the company’s sales base relative to what similar businesses and the tailored fair multiple would imply.

Taken together, the P/S work points to ICON stock appearing undervalued on sales compared with both peers and its own fair multiple.

The ICON Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for ICON help you see what kind of future the current price assumes. They link the valuation work above to explicit paths for ICON's growth, margins and earnings, and set out what would need to happen for the stock to be worth meaningfully more or less than today. Where a ratio or model gives you a single number, Narratives describe the future behind that number so you can watch how it plays out over time on the Community page.

Community views on ICON sit far apart, with one side focused on recovery potential and the other on margin and contract risk.

Bull case: 9% undervalued

"ICON has demonstrated resilience amidst macro uncertainties by focusing on strategic partnerships and opportunities in the midsized pharma segment, which could contribute to future revenue growth…"

Bear case: 6% overvalued

"Intensifying price competition, as acknowledged by management and reinforced by large pharma clients under patent cliff pressures, threatens to erode ICON's gross and EBITDA margins in the coming years…"

Do you think there's more to the story for ICON? Head over to our Community to see what others are saying!

The Bottom Line

ICON screens as undervalued on both its Discounted Cash Flow (DCF) intrinsic value estimate and on revenue based multiples, which points to a clear valuation gap rather than a mixed signal. The broader checks also lean supportive, so the burden of proof now sits with concerns around execution on AI driven growth and the company’s debt profile. For you as an investor, the key question is whether ICON can sustain cash generation and margins enough for that discount to close, or whether the current price simply reflects ongoing financing and competitive risks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.